Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: Results from a pilot study

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Goldfien, Robert D ^a   Ng, Michele S ^a   Yip, Goldie ^a   Hwe, Alice ^a   Jacobson, Alice ^b   Pressman, Alice ^b   Avins, Andrew L ^b  

^a Kaiser Permanente ^*  (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROBENECID; URIC ACID; ANTIGOUT AGENT;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONSULTATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE TITRATION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; GOUT; HEALTH PROGRAM; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHARMACEUTICAL CARE; PHARMACIST; PROGRAM EFFECTIVENESS; PROPHYLAXIS; RECURRENT DISEASE; RHEUMATOLOGY; URIC ACID BLOOD LEVEL; VERY ELDERLY; BLOOD; HOSPITAL PHARMACY; PATIENT CARE PLANNING; PILOT STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; AMBULATORY CARE FACILITIES; CHRONIC DISEASE; FEASIBILITY STUDIES; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PATIENT CARE PLANNING; PHARMACY SERVICE, HOSPITAL; PILOT PROJECTS; TREATMENT OUTCOME; URIC ACID;

EID: 84892839848     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003627     Document Type: Article

References (28)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008;58:26-35.
2. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol 2008;35:498-501. (Pubitemid 351374428)
3. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-6.
4. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6. (Pubitemid 35266034)
5. Kramer HN, Curhan G. The association between gout and neprholithiasis: the National Health and Nutrition Examination Survey III. Am J Kidney Dis 2002;40:37-42. (Pubitemid 34701209)
6. Weaver AL. Epidemiology of gout. Cleve Clin J Med 2008;75(Supp 5):9-12.
7. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6. (Pubitemid 351956658)
8. Peters AL, Davidson MB. Application of a diabetes managed care program. The feasibility of using nurses and a computer system to provide effective care. Diabetes Care 1998;21:1037-43. (Pubitemid 28368504)
9. Zhang W. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
10. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.
11. Edwards NL. Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep 2010;13:154-9.
12. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269-70. (Pubitemid 47492466)
13. Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9. (Pubitemid 46932089)
14. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheum 2008;20:167-72. (Pubitemid 351339888)
15. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43. (Pubitemid 351466455)
16. Schumacher HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2008;48:188-94.
17. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103. (Pubitemid 38298989)
18. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
19. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50. (Pubitemid 44168841)
20. Mandell BF. Confessions of a goutophile: despite its treatability, gout remains a problem. Cleve Clin J Med 2008;75(Suppl 5):S1.
21. Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617. (Pubitemid 36805619)
22. Trifiro G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2012;72:694-700.
23. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2012 [cited 2013 Apr 12]. http://ard.bmj.com/cgi/doi/10.1136/ annrheumdis-2012-201676
24. Liote F, Choi H. Managing gout needs more than drugs: 'II faut le savoir-faire, I'Art et la maniere'. Ann Rheum Dis 2013;72:791-3.
25. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
26. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheum Rep 2009;11:135-40.
27. Kim SC, Newcomb C, Margolis D, et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res 2013;65:578-84.
28. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007;20:391-5.